76,210 Shares in Boston Scientific Corporation $BSX Bought by Wealthfront Advisers LLC

Key Points

• Wealthfront Advisers initiated a Boston Scientific position by purchasing 76,210 shares worth approximately $3.25 million. Institutional investors own 89.07% of the company, with several other funds also increasing their holdings.
• Boston Scientific reported stronger-than-expected quarterly results, with EPS of $0.86 versus the $0.83 consensus and revenue of $5.44 billion, up 7.5% year over year. The company provided third-quarter and full-year 2026 EPS guidance.
• Directors purchased shares recently, while the company authorized a $5 billion stock-repurchase program. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $71.62.

Wealthfront Advisers LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 76,210 shares of the medical equipment provider's stock, valued at approximately $3,253,000.

Several other large investors also recently modified their holdings of BSX. Brighton Jones LLC increased its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter worth $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its position in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after acquiring an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last quarter. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX opened at $49.47 on Friday. The stock has a market capitalization of $71.69 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a fifty day simple moving average of $46.26 and a 200 day simple moving average of $57.91. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the business earned $0.75 EPS. The company's revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages recently weighed in on BSX. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research note on Wednesday, July 29th. Daiwa Securities Group downgraded Boston Scientific from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Mizuho reduced their price objective on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Finally, TD Cowen decreased their price objective on Boston Scientific from $61.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source